1. Azevedo CJ, Kutz C, Dix A, Boster A, Sanossian N, Kaplan J (2019) Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol [Internet] 18(4):329–31. https://doi.org/10.1016/S1474-4422(19)30076-6
2. FDA (2019) Boxed Warning, FDA: Alemtuzumab Stroke. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-serious-risks-stroke-and-blood-vessel-wall-tears-multiple-sclerosis-drug
3. European Medicines Agency (2020) Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada. https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada. Accessed 31 Jan 2021
4. Myro AZ, Bjerke G, Zarnovicky S, Holmøy T (2018) Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report. BMC Pharmacol Toxicol 19(1):1–4
5. Uppsala Monitoring Centre. (2022) VigiBase, the World Health Organization international database of suspected adverse drug reactions. https://www.who-umc.org/vigibase/vigibase/. Accessed 1 Mar 2022.